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IORT staff and could provide a provisional plan that includes 
also DVH and MU calculation.  
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Purpose or Objective: Monte Carlo (MC) recalculation of 
spot-scanning proton therapy treatment plans can provide an 
independent verification of monitor units required for 
delivery, and reduce the time treatment rooms need to be 
reserved for patient specific QA. We describe the 
development of such a MC verification system for a clinical 
facility. 
 
Material and Methods: Realistic clinical beam models were 
developed by matching simulations (using GATE/GEANT4) to 
measurements made in a clinical beamline. They consist of a 
tuned physics list, a lookup table relating each of the 115 
nominal beam energies to a tuned spot energy (mean and 
standard deviation) and phase space parameters which allow 
spot sizes to be properly modeled for any combination of 
energy and nozzle extension. For all beam energies 
simulations accurately reproduce both integral depth dose 
profiles (>97% of data-points pass a local gamma analysis at 
2%/2mm) and lateral profiles measured in air and in solid 
water (with a 0.2 mm maximum difference). The model was 
further validated against a series of simple test plans which 
were optimized in the clinical Treatment Planning System 
(TPS) to produce uniform dose volumes at various depths in 
water.The automated MC system can process, simulate and 
analyse treatment plans without user input once it receives 
the TPS files. 
 
Results: 
 
 
 
The system was tested for a three field (11k spot) base of 
skull treatment plan computed in a patient CT dataset. 
Simulations were split into 40 calculations over a 10 quad-
core CPU cluster, requiring <30 minutes to achieve dosimetric 
uncertainties (within the 90% isodose volume) of <1%. The 
figure demonstrates the broad agreement between the TPS 
(left) and the MC simulation (right). The local gamma pass 
rate between the two (bottom) is 97% at 4%/4mm (green 
voxels pass, red / blue voxels fail). This should be 
interpreted in the context of this being a highly 
inhomogeneous target site: Differences occurred only in 
heterogeneous regions where the TPS’s analytical dose 
calculation would be expected to model dose deposition less 
accurately than MC systems. For example, the MC simulations 
predict a lower dose around the sinus air cavities than the 
TPS. 
 
Conclusion: We have demonstrated that the MC verification 
system can accurately reproduce the dose distribution 
predicted by a clinical TPS. Further validation work is 
ongoing using a variety of plans and phantom measurements. 
Once clinically commissioned, the system can be used as an 
independent dose checker, reducing on-set verification time. 
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Purpose or Objective: To establish the workflow & 
methodology and to perform an experimental validation of 
treatment plan conversion from Tomotherapy HD machine 
(Accuray) using dynamic jaws to a True Beam (Varian) Linac. 
For this purpose, the RayStation (RS) TPS using fallback 
planning (RFP) is currently tested. An end-to-end set of 
phantom configurations of increasing complexity are 
presented. The ultimate goal is to validate this process in 
order to minimize the impact of machine downtime on 
patient treatments. 
 
Material and Methods: Four phantom based treatment plans 
were generated in the Tomotherapy Planning Station. These 
plans were mimicked with RFP for the TrueBeam using X6-FFF 
dual-arc VMAT. The first three cases planned on the Cheese 
Phantom (Std. Imaging) consisted of 1 to 4 target dose levels 
and 3 OARs, using heterogeneous inserts for the last one. The 
4th case was an integrated boost H&N treatment with 3 
target dose levels planned on an anthropomorphic phantom 
(H&N, IBA). Original Helical Tomotherapy (HT) and RS 
fallback plans were delivered respectively on each machine. 
Ion chamber (A1SL, Std. Imaging) and Gafchromic EBT3 (ISP) 
films were used to measure absolute and planar doses. First, 
for both machines beam delivery vs. treatment plan was 
evaluated as a baseline for absolute dose, gamma (γ) passing 
rate (criteria 3%/3mm) and overall uncertainties. Secondly, 
in order to ensure that the difference between the two 
calculated dose distributions (TPS_TOMO / TPS_RAYSTATION) 
matched the differences between the two measured film 
dose distributions (Film_TOMO / Film_RAYSTATION), a γ 
difference (5%/5mm) was performed. 
 
 
 
Results: First, gamma evaluation was (99.1±0.6)% for HT and 
(99.5±0.4)% for RS fallback plans while absolute dose 
differences between calculations and ion chamber 
measurements were respectively 0.9% for HT and -0.7% for RS 
on average for all end-to-end tests. Secondly, average γ 
difference between calculated doses TPS_TOMO / 
